Chronic Versus Acute: Rethinking Dry Eye Disease

This activity is supported by an unrestricted educational grant from Kala Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Describe how DED symptoms can impact patient quality of life.
• Explain how inflammation is a key driver of DED pathogenesis and symptomatology.
• Describe how episodic flares are part of the inflammatory disease process.
• Formulate an individualized treatment plan for patients experiencing DED flares.
• Compare available data on agents in the pipeline and their potential significance for DED management.

Accreditation and Designation Statement

Sponsored by:
This activity, COPE Activity Number 121665, is accredited by COPE for continuing education for optometrists. 
This course is approved for 1 hours CE. 
COPE Course ID: 72451-AS
COPE Activity ID: 121665

Participation Method

In order to obtain credit, you must read the activity in its entirety and complete the Pretest/Posttest/Activity Evaluation/Satisfaction Measures Form, which consists of a series of multiple-choice questions.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bruder, Dompé, HanAll Bio, Kala Pharmaceuticals, Novartis, Osmotica, Oyster Point Pharma, Sight Sciences, Tarsis, Thea, and Topivent. Grant/Research: Allergan,  Kala Pharmaceuticals, NIH, and Tear Science. Stock/Shareholder: Acquiom, Alcon Vision, LacriScience, and Tear Film Innovations.

Douglas K. Devries, OD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Advisory Board: Akorn, Alcon, Allergan, Avelino, Azura, Bausch + Lomb, BlephEx, Bio Tissue, Bruder, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, OcuSoft, Quidel, Sight Sciences, Science Based Health, Sun Pharmaceutical Industries, Tarsus, Tearlab, Thea, and Visus. Speaker’s Bureau: Allergan, Bausch + Lomb, Bio Tissue, BlephEx, Bruder, Eyevance, Kala Pharmaceuticals, Lumenis, Johnson & Johnson Vision, OcuSoft, Sight Sciences, Science Based Health, Sun Pharmaceutical Industries, and Tearlab. Stock/Shareholder: RPS.

Justin Schweitzer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompé, EyePoint, Horizon, Ocular Therapeutix, and Reichert. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceutical Industries. Share/Stockholder: Equinox.

Mile Brujic, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Akorn, Alcon Vision, Allergan, Bausch + Lomb Health, Blephex, Contamac, CSEye, Eyevance, Horizon Therapeutics, Kala Pharmaceuticals, Novartis, Sun Pharmaceutical Industries, VMax Vision, and Zea Vision. Speaker’s Bureau: Allergan, Bausch + Lomb Health, Kala Pharmaceuticals, Novartis, Optovue, Sun Pharmaceutical Industries, and Zea Vision. Grant/Research Support: Contamac.

Selina R. McGee, OD, FAAO, Dipl ABO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Cynosure, Dompe, Eyevance, Horizon, Kala Pharmaceuticals, Lumenis, Novartis, Optovue, Versant, and Vertical. Speaker’s Bureau: Allergan, Lumenis, and Optovue.

Walter O. Whitley, OD, MBA, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Bausch + Lomb, Bio-Tissue, Bruder Healthcare, Eyevance, Glaukos, Horizon Therapeutics, Johnson & Johnson Vision, Kala Pharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Ocusoft, Oyster Point Pharma, Quidel, Regener-Eyes, RVL Pharmaceuticals, ScienceBased Health, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, TearLab, and Thea Pharmaceuticals. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Vision, Bausch + Lomb, Bio-Tissue, Eyevance, Novartis, ScienceBased Health, and Sun Pharmaceutical Industries. Share/Stockholder: Leo Lens Technology.

The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Modern Optometry, or Kala Pharmaceuticals.